Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-2 PREVENT Inclisiran Outcomes Trial in Established Cardiovascular Disease (Japan)
jRCT2031220634Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, myocardial infarction (MI), ischemic stroke and 1 more comparing Inclisiran 300 mg SC with Placebo SC (2 arms). Primary endpoint: Time to First Occurrence of 3P-MACE. Started Apr 2023; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
atherosclerotic diseasemyocardial infarction (MI)ischemic strokearteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT2031220634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220634.